Update on Immune Checkpoint Inhibitors in Lung Cancer

Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)

(2017) M. Sznol et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of bavituximab plus paclitaxel and carboplatin in untreated locally advanced or metastatic non-small cell lung cancer: Interim results.

(2017) R. Digumarti et al.   JOURNAL OF CLINICAL ONCOLOGY

L02.04 * AMP-224, A FUSION PROTEIN THAT TARGETS PD-1

(2013) F. Smothers et al.   ANNALS OF ONCOLOGY

Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial

(2013) Hubert Serve et al.   JOURNAL OF CLINICAL ONCOLOGY

Reciprocal Relationship between Myeloid-Derived Suppressor Cells and T Cells

(2013) S. Nagaraj et al.   JOURNAL OF IMMUNOLOGY

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

(2013) Luana Calabrò et al.   LANCET ONCOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phosphatidylserine-Targeting Antibody Induces M1 Macrophage Polarization and Promotes Myeloid-Derived Suppressor Cell Differentiation

(2013) Y. Yin et al.   Cancer Immunology Research

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer

(2012) Hui Liu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

(2012) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response

(2012) Cheng Chen et al.   EXPERIMENTAL CELL RESEARCH

Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer

(2012) Carlo Genova et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population

(2012) Andrzej Wiśniewski et al.   HUMAN IMMUNOLOGY

Interleukin-27 Priming of T Cells Controls IL-17 Production In trans via Induction of the Ligand PD-L1

(2012) Kiyoshi Hirahara et al.   IMMUNITY

Increased numbers but functional defects of CD56+CD3+ cells in lung cancer

(2012) S. Y. Al Omar et al.   INTERNATIONAL IMMUNOLOGY

Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors

(2012) Hélène Salmon et al.   JOURNAL OF CLINICAL INVESTIGATION

The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs

(2012) Saroj Niraula et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

B7-DC-Ig Enhances Vaccine Effect by a Novel Mechanism Dependent on PD-1 Expression Level on T Cell Subsets

(2012) M. Mkrtichyan et al.   JOURNAL OF IMMUNOLOGY

Impact of Collection and Storage of Lung Tumor Tissue on Whole Genome Expression Profiling

(2012) Maxim B. Freidin et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Prognostic implications of human leukocyte antigen class I expression in patients who underwent surgical resection for non–small-cell lung cancer

(2012) Takeshi Hanagiri et al.   JOURNAL OF SURGICAL RESEARCH

When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression

(2012) G. R. Oxnard et al.   JNCI-Journal of the National Cancer Institute

Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy

(2012) Alexander Drilon et al.   LANCET ONCOLOGY

Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC)

(2012) Nasrollah Erfani et al.   LUNG CANCER

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

(2012) Hirokazu Matsushita et al.   NATURE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Within tumors, interactions between T cells and tumor cells are impeded by the extracellular matrix

(2012) Hélène Salmon et al.   OncoImmunology

Involvement of STAT3 in immune evasion during lung tumorigenesis

(2012) Hiroshi Kida et al.   OncoImmunology

Lung Cancer Vaccines

(2011) Ronan J. Kelly et al.   CANCER JOURNAL

Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment

(2011) A. M. Lesokhin et al.   CANCER RESEARCH

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

New Challenges in Endpoints for Drug Development in Advanced Melanoma

(2011) A. Ribas et al.   CLINICAL CANCER RESEARCH

Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors

(2011) D. E. Gerber et al.   CLINICAL CANCER RESEARCH

Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms

(2011) Mikayel Mkrtichyan et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

High transforming growth factor β expression represents an important prognostic parameter for surgically resected non–small cell lung cancer

(2011) William Sterlacci et al.   HUMAN PATHOLOGY

Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer

(2011) Suliman Y. Al Omar et al.   IMMUNOLOGY

The Challenge and Promise of the Genomic Era

(2011) George W. Sledge   JOURNAL OF CLINICAL ONCOLOGY

PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice

(2011) Taku Okazaki et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Non-small Cell Lung Cancer Induces an Immunosuppressive Phenotype of Dendritic Cells in Tumor Microenvironment by Upregulating B7-H3

(2011) Thomas Schneider et al.   Journal of Thoracic Oncology

Delivering affordable cancer care in high-income countries

(2011) Richard Sullivan et al.   LANCET ONCOLOGY

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

(2011) Alice T Shaw et al.   LANCET ONCOLOGY

6thAnnual European Antibody Congress 2010

(2011) Alain Beck et al.   mAbs

NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation

(2010) A. T. Bjorklund et al.   BLOOD

Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

(2010) Yan Zhang et al.   Cellular & Molecular Immunology

PD-L1 expression on tolerogenic APCs is controlled by STAT-3

(2010) Sabine J. Wölfle et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors

(2010) Suliman Al Omar et al.   HUMAN IMMUNOLOGY

Addition of Bevacizumab to Chemotherapy for Treatment of Solid Tumors: Similar Results but Different Conclusions

(2010) Alberto Ocaña et al.   JOURNAL OF CLINICAL ONCOLOGY

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

(2010) Chuan-Yong Mu et al.   MEDICAL ONCOLOGY

Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

(2010) Junko Matsuzaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer

(2009) Hester van Cruijsen et al.   BMC CANCER

The Prevalence of FOXP3+ Regulatory T-Cells in Peripheral Blood of Patients with NSCLC

(2009) Liu Li et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer

(2009) A. Lin et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Diagnosis value of serum B7-H3 expression in non-small cell lung cancer

(2009) Guangbo Zhang et al.   LUNG CANCER

Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill tumor cells

(2008) Paolo Carrega et al.   CANCER

Alteration of the immunological synapse in lung cancer: a microenvironmental approach

(2008) S. Derniame et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures

(2008) Marie-Caroline Dieu-Nosjean et al.   JOURNAL OF CLINICAL ONCOLOGY